Bicycle Therapeutics Signs Clinical Development Partnership with Cancer Research UK for BT7401

 Bicycle Therapeutics Signs Clinical Development Partnership with Cancer Research UK for BT7401

Bicycle Therapeutics Signs Clinical Development Partnership with Cancer Research UK for BT7401

Shots:

  • Cancer Research UK to get upfront in cash and equity, success-based milestones, royalties and will fund & sponsor the development of BT7401 from preclinical to the P-IIa trial. Bicycle to get rights to advance BT7401 program
  • The focus of the collaboration is to get insights on biologic and therapeutic profile of BT7401 candidate which can be used for patients who stop responding to checkpoint inhibitors
  • BT7401 is a multivalent Bicycle CD137 agonist and has shown durable anti-tumor effects with significant pharmacologic activity in preclinical models. Bicycle’s BT1718 is also a Bicycle Toxin Conjugate (BTC) that targets MT1-MMP and is evaluated in P-I/IIa trial

Click here to read full press release/ article | Ref: Bicycle Therapeutics | Image: Twitter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post